瑞典、挪威和丹麦慢性荨麻疹真实临床实践基线结果:AWARE非干预多中心研究
AWARE研究是一项前瞻性、非干预性、多国伞式研究,纳入成年H1抗组胺药难治性慢性荨麻疹患者。本文报告丹麦、挪威和瑞典7个中心共158例患者的基线数据,显示75.6%患者荨麻疹未控制(UCT<12),平均DLQI为7.7,医疗资源使用率高,基线访视时药物治疗率从入组前的60.1%升至96.2%。
要点
- H1抗组胺药难治性慢性荨麻疹患者中75.6%荨麻疹未控制(UCT<12)。
- 患者生活质量中度受损,平均DLQI评分为7.7。
- 基线访视时药物治疗率从入组前的60.1%升至96.2%。
核心结论
- 斯堪的纳维亚成年H1抗组胺药难治性慢性荨麻疹患者医疗资源使用率高且生活质量受损。
- 研究入组前药物治疗率较低,但基线访视时几乎增至100%。
研究设计与样本
- AWARE为前瞻性、非干预性、多国伞式研究,纳入确诊慢性荨麻疹(>2个月)且对H1抗组胺药难治的成人(≥18岁)。
- 本基线分析纳入丹麦(n=80)、挪威(n=50)和瑞典(n=28)7个中心共158例患者。
主要发现
- 患者平均年龄40.3岁,平均BMI 26.5 kg/m2,女性占69.6%。
- 75.6%患者荨麻疹未控制(UCT评分<12);61.4%为慢性自发性荨麻疹(CSU),20.3%同时有CSU和慢性诱导性荨麻疹。
- 常见合并症包括哮喘(19.6%)、过敏性鼻炎(16.5%)和食物过敏(8.2%)。
- 入组前60.1%患者报告使用荨麻疹治疗,包括非镇静H1抗组胺药(40.5%)、糖皮质激素(19%)、孟鲁司特(14.6%)和奥马珠单抗(8.2%);基线访视时药物治疗率升至96.2%。
- 患者生活质量中度受损(平均DLQI评分7.7),医疗资源使用率高。
临床怎么用
- 真实实践中H1抗组胺药难治性慢性荨麻疹患者疾病控制和生活质量仍不理想,需关注并优化治疗。
- 研究入组前药物治疗率偏低,提示真实临床中可能存在治疗不足,应规范评估并提高治疗率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic urticaria (CU) is characterized by the recurrence of itchy hives and/or angioedema for more than 6 weeks. AWARE (A World-wide Antihistamine-Refractory Chronic Urticaria Patient Evaluation) is a multinational study designed to document the real-life treatment situation, burden of disease and clinical resource usage of H1-antihistamine-refractory CU patients. OBJECTIVE: To examine baseline data from Scandinavian AWARE patients. METHODS: AWARE is a prospective, non-interventional, multinational, umbrella design study, which includes adults (≥18 years) with a confirmed CU diagnosis (>2 months) that is refractory to H1-antihistamines. Baseline patient characteristics, disease activity (urticaria control test [UCT]), pharmacological treatment, comorbidities and healthcare usage were documented by the treating physician. Quality of life (QoL; dermatology life quality index [DLQI]; chronic urticaria quality of life questionnaire [CU-Q2 oL; Danish patients only]) and work productivity and activity impairment (WPAI) scores were also assessed. RESULTS: Overall, 158 CU patients from seven centres in Denmark (n = 80), Norway (n = 50) and Sweden (n = 28) were included in this baseline analysis. Mean age and BMI were 40.3 years and 26.5 kg/m2 , respectively. The majority of patients were female (69.6%), had uncontrolled CU (75.6%; UCT score <12) and had a 'spontaneous' component to their CU (61.4% CSU; 20.3% both CSU and chronic inducible urticaria). Common comorbidities included asthma (19.6%), allergic rhinitis (16.5%) and food allergies (8.2%). Overall, 60.1% of patients reported using treatments for CU including non-sedative H1-antihistamines (40.5%), corticosteroids (19%), montelukast (14.6%) and omalizumab (8.2%). Pharmacological treatment rates increased to 96.2% during the baseline visit. On average, patient QoL was moderately affected (mean DLQI score 7.7) and healthcare resource usage was high. CONCLUSION: Adult Scandinavian H1-antihistamine-refractory CU patients reported high rates of healthcare usage and QoL impairment. Rates of pharmacological treatment use were low before study enrolment but increased to almost 100% during the baseline visit.
引用
- Thomsen SF, Pritzier EC, Anderson CD, et al. Chronic urticaria in the real-life clinical practice setting in Sweden, Norway and Denmark: baseline results from the non-interventional multicentre AWARE study. J Eur Acad Dermatol Venereol. 2017. PMID: 28294420. doi:10.1111/jdv.14210
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。